主流化癌症遗传学:将胚系BRCA检测整合至常规卵巢癌门诊的模型
该研究在妇科肿瘤门诊嵌入遗传咨询师,对高级别非黏液性上皮性卵巢癌患者实施胚系BRCA1/2检测主流化模型,回顾性审计两个连续一年期。64名女性接受检测,BRCA1/2致病性变异检出率为17%,符合条件女性的转诊率显著增至90%以上(p<0.001),从转诊到获得检测结果的中位时间不足5个月,超过90%的患者在一线化疗期间获得结果,遗传咨询时间从120分钟降至54分钟,癌症专科医生对该模型感到满意。
要点
- 主流化模型使符合条件患者的遗传检测接受率提高至90%以上。
- BRCA1/2致病性变异检出率为17%,中位结果回报时间不足5个月。
- 遗传咨询时间从120分钟降至54分钟,癌症专科医生对该模型感到满意。
核心结论
- 主流化模型有效,将符合条件患者的遗传检测接受率提高至90%以上。
- 该模型对患者、遗传咨询师和癌症专科医生高效,且为癌症专科医生所接受。
- 该模型促进了遗传与肿瘤服务的同址提供,同时将遗传检测的临床责任分离至专科遗传服务,确保以患者为中心的准确和稳健的照护。
研究设计与样本
- 通过嵌入妇科肿瘤门诊的遗传咨询师,对符合条件的高级别非黏液性上皮性卵巢癌女性实施胚系BRCA1/2检测主流化模型。
- 该模型包括专用转诊表格、每周由遗传学主导的多学科转诊审查,以及在化疗椅旁时间由嵌入的遗传咨询师提供检测前后遗传咨询。
- 对实施后两个连续一年期的性能和结局进行回顾性审计,包括关于医学专科医生对主流化及该模型舒适度的调查数据。
主要发现
- 在实施后两年期间,64名女性接受了主流化BRCA1/2检测,BRCA1/2致病性变异检出率为17%。
- 符合条件女性的转诊率显著增加至90%以上(p<0.001)。
- 从转诊到提供遗传检测结果的中位时间不足5个月,超过90%的患者在一线化疗期间获得结果。
- 遗传咨询时间从120分钟降至54分钟。
- 癌症专科医生对该模型感到舒适。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Owing to the rapid increase in clinical need, we aimed to implement and review the performance of a mainstreaming model of germline BRCA1/2 genetic testing in eligible women with high grade non-mucinous epithelial ovarian cancer via a Genetic Counselor embedded in the gynecology oncology clinic. METHODS: The model implemented involved a specialized referral form, weekly genetics-lead multidisciplinary review of referrals, and pre- and post-test genetic counseling provided by an embedded genetic counselor during chemotherapy chair time. Performance and outcomes were retrospectively audited over the following two consecutive one year periods, including survey data on medical specialist comfort with mainstreaming and the model. RESULTS: Sixty-four women underwent mainstreamed BRCA1/2 testing over the two year post-implementation period with a rate of detection of BRCA1/2 pathogenic variants of 17%. The referral rate for eligible women significantly increased to over 90% (p<0.001). The median time from referral to delivery of genetic testing results was less than five months, with >90% of patients receiving results during first line chemotherapy. Genetic counseling time decreased from 120 to 54min. Cancer specialists were comfortable with the model. CONCLUSIONS: The mainstreaming model proved effective, increasing uptake of genetic testing in eligible patients to over 90%; it was efficient for patients, genetic counselors and cancer specialists and acceptable to cancer specialists. It facilitated co-location of genetic and oncology service delivery but separation of clinical responsibility for genetic testing to a specialist genetics service, ensuring accurate and robust patient-centred care.
引用
- Kentwell M, Dow E, Antill Y, et al. Mainstreaming cancer genetics: A model integrating germline BRCA testing into routine ovarian cancer clinics. Gynecol Oncol. 2017. PMID: 28162234. doi:10.1016/j.ygyno.2017.01.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。